Arvinas to report Q1 2026 financials and corporate update on May 12 via live webcast

Arvinas, a biotech company specializing in targeted protein degradation drugs, will present its first quarter 2026 financial results and provide a corporate update on May 12, 2026, via a live webcast. The company is known for developing the first FDA-approved PROTAC drug, VEPPANU, for advanced breast cancer, and is advancing several investigational drugs for neurodegenerative diseases and cancers. Investors and interested parties can access the webcast on Arvinas' website, with a replay available after the event. This update is important as it offers insights into the company's progress and financial health amid ongoing drug development.